newsfilter
← Latest News
GlobeNewswire·

PLx Pharma Inc. Reports Third Quarter 2020 Results and Provides Business Update

--Announces $18 million private placement-- --Submitted sNDAs for VAZALORE 325 mg and 81 mg doses to FDA end of October-- --On target for third quarter 2021 commercial launch of VAZALORE-- SPARTA,...